OBJECTIVE: Repeated exposure to carboplatin can lead to hypersensitivity reactions during retreatment with carboplatin. This may prevent its further use in platinum-sensitive ovarian cancer patients. At our institution, an increasing proportion of patients are prophylactically converted to an extended schedule of infusion after 8 cycles of carboplatin. We sought to determine whether an incrementally increasing, extended 3-hour infusion of carboplatin with appropriate premedication was associated with a lower rate of hypersensitivity reactions compared to the standard 30-minute schedule in sequentially treated patients. METHODS: We performed a retrospective electronic medical record review of patients with recurrent ovarian cancer retreated with carboplatin at our institution from January 1998 to December 2008. RESULTS: Seven hundred and seventy-seven patients with relapsed ovarian, fallopian tube, or primary peritoneal cancer were retreated with carboplatin and met study inclusion criteria. Of these, 117 (17%) developed hypersensitivity reactions during second-line or greater carboplatin-based treatment for recurrent disease. Only 6 (3.4%) of the 174 patients who received the extended schedule developed hypersensitivity reactions (0% grade 4; 50% grade 3) compared to 111 (21%) of 533 patients in the standard schedule group (13% grade 4; 77% grade 3). The first hypersensitivity episode occurred after a median of 16 platinum (carboplatin and cisplatin) treatments in the extended group compared to 9 in the standard group. Using the Fisher exact test, there was an association with a reduced incidence of hypersensitivity reactions with the extended infusion schedule (P<0.001). CONCLUSION: Our data suggest appropriate premedication and prophylactic conversion to an extended infusion during carboplatin retreatment may reduce hypersensitivity reactions.
OBJECTIVE: Repeated exposure to carboplatin can lead to hypersensitivity reactions during retreatment with carboplatin. This may prevent its further use in platinum-sensitive ovarian cancerpatients. At our institution, an increasing proportion of patients are prophylactically converted to an extended schedule of infusion after 8 cycles of carboplatin. We sought to determine whether an incrementally increasing, extended 3-hour infusion of carboplatin with appropriate premedication was associated with a lower rate of hypersensitivity reactions compared to the standard 30-minute schedule in sequentially treated patients. METHODS: We performed a retrospective electronic medical record review of patients with recurrent ovarian cancer retreated with carboplatin at our institution from January 1998 to December 2008. RESULTS: Seven hundred and seventy-seven patients with relapsed ovarian, fallopian tube, or primary peritoneal cancer were retreated with carboplatin and met study inclusion criteria. Of these, 117 (17%) developed hypersensitivity reactions during second-line or greater carboplatin-based treatment for recurrent disease. Only 6 (3.4%) of the 174 patients who received the extended schedule developed hypersensitivity reactions (0% grade 4; 50% grade 3) compared to 111 (21%) of 533 patients in the standard schedule group (13% grade 4; 77% grade 3). The first hypersensitivity episode occurred after a median of 16 platinum (carboplatin and cisplatin) treatments in the extended group compared to 9 in the standard group. Using the Fisher exact test, there was an association with a reduced incidence of hypersensitivity reactions with the extended infusion schedule (P<0.001). CONCLUSION: Our data suggest appropriate premedication and prophylactic conversion to an extended infusion during carboplatin retreatment may reduce hypersensitivity reactions.
Authors: H Kook; K M Kim; S H Choi; B S Choi; H J Kim; S Y Chung; S J Choi; T J Hwang Journal: Bone Marrow Transplant Date: 1998-04 Impact factor: 5.483
Authors: K M Zanotti; L A Rybicki; A W Kennedy; J L Belinson; K D Webster; B Kulp; G Peterson; M Markman Journal: J Clin Oncol Date: 2001-06-15 Impact factor: 44.544
Authors: Joanna R Schwartz; Christina Bandera; AnnMarie Bradley; Laurent Brard; Robert Legare; C O Granai; Don S Dizon Journal: Gynecol Oncol Date: 2006-12-08 Impact factor: 5.482
Authors: A H Calvert; S J Harland; D R Newell; Z H Siddik; A C Jones; T J McElwain; S Raju; E Wiltshaw; I E Smith; J M Baker; M J Peckham; K R Harrap Journal: Cancer Chemother Pharmacol Date: 1982 Impact factor: 3.333
Authors: Mariana C Castells; Nichole M Tennant; David E Sloane; F Ida Hsu; Nora A Barrett; David I Hong; Tanya M Laidlaw; Henry J Legere; Samridhi N Nallamshetty; Ross I Palis; Jayanti J Rao; Suzanne T Berlin; Susana M Campos; Ursula A Matulonis Journal: J Allergy Clin Immunol Date: 2008-05-27 Impact factor: 10.793
Authors: Paul E Hesterberg; Aleena Banerji; Eyal Oren; Richard T Penson; Carolyn N Krasner; Michael V Seiden; Johnson T Wong Journal: J Allergy Clin Immunol Date: 2009-06 Impact factor: 10.793
Authors: Katherine LaVigne; David M Hyman; Qin C Zhou; Alexia Iasonos; William P Tew; Carol Aghajanian; Vicky Makker; Martee L Hensley; Jason Konner; Rachel N Grisham; Nicholas Cangemi; Krysten Soldan; David R Spriggs; Paul J Sabbatini; Roisin E OʼCearbhaill Journal: Int J Gynecol Cancer Date: 2018-07 Impact factor: 3.437
Authors: Nektaria Makrilia; Ekaterini Syrigou; Ioannis Kaklamanos; Leonidas Manolopoulos; Muhammad Wasif Saif Journal: Met Based Drugs Date: 2010-09-20